Paul Tudor Jones's AXSM Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 18,950 shares of Axsome Therapeutics, Inc. (AXSM) worth $4.64 M, representing 0.01% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in AXSM, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2021, adding 63,668 shares. Largest reduction occurred in Q4 2021, reducing 46,055 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Axsome Therapeutics (AXSM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Axsome Therapeutics (AXSM) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +18,950 | New Buy | 18,950 | $244.77 |
| Q2 2025 | -40,866 | Sold Out | 0 | $0.00 |
| Q1 2025 | +40,866 | New Buy | 40,866 | $116.63 |
| Q4 2024 | -25,832 | Sold Out | 0 | $0.00 |
| Q3 2024 | +6,849 | Add 36.08% | 25,832 | $89.87 |
| Q2 2024 | +18,983 | New Buy | 18,983 | $80.50 |
| Q3 2023 | -30,321 | Sold Out | 0 | $0.00 |
| Q2 2023 | +6,453 | Add 27.04% | 30,321 | $71.86 |
| Q1 2023 | +23,868 | New Buy | 23,868 | $0.06 |
| Q4 2022 | -20,580 | Sold Out | 0 | $0.00 |
| Q3 2022 | -23,282 | Reduce 53.08% | 20,580 | $44.61 |
| Q2 2022 | -34,105 | Reduce 43.74% | 43,862 | $38.30 |
| Q1 2022 | +33,693 | Add 76.10% | 77,967 | $41.39 |
| Q4 2021 | -46,055 | Reduce 50.99% | 44,274 | $37.79 |
| Q3 2021 | +63,668 | Add 238.81% | 90,329 | $32.96 |
| Q2 2021 | -16,667 | Reduce 38.47% | 26,661 | $67.48 |
| Q1 2021 | +38,925 | Add 884.06% | 43,328 | $56.61 |
| Q4 2020 | -8,978 | Reduce 67.10% | 4,403 | $81.54 |
| Q3 2020 | +7,002 | Add 109.77% | 13,381 | $71.22 |
| Q2 2020 | +6,379 | New Buy | 6,379 | $82.30 |
| Q1 2020 | -23,473 | Sold Out | 0 | $0.00 |
| Q4 2019 | +23,473 | New Buy | 23,473 | $103.35 |
Paul Tudor Jones's Axsome Therapeutics Investment FAQs
Paul Tudor Jones first purchased Axsome Therapeutics, Inc. (AXSM) in Q4 2019, acquiring 23,473 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Axsome Therapeutics, Inc. (AXSM) for 22 quarters since Q4 2019.
Paul Tudor Jones's largest addition to Axsome Therapeutics, Inc. (AXSM) was in Q3 2021, adding 90,329 shares worth $2.98 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 18,950 shares of Axsome Therapeutics, Inc. (AXSM), valued at approximately $4.64 M.
As of the Q2 2026 filing, Axsome Therapeutics, Inc. (AXSM) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Axsome Therapeutics, Inc. (AXSM) was 90,329 shares, as reported at the end of Q3 2021.